Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Forum
  • About Us
    • Our Coverage
    • Team
Press release

Redeye: Magle Chemoswed Q4 - Delivering on its growth trajectory

Magle Chemoswed Holding

Redeye provides a research update following the Q4 report recently published by Magle. The company continues to report record-high sales figures at SEK87.2, a 52% y/y growth, and a promising EBITDA margin at 24% following the integrations of pK Chemicals and Amniotics. As the company has now strengthened its financials through recent share issues, we believe that the new Magle Group is poised to continue its growth and generate further shareholder value ahead.

Read more and download the Research Update.
 
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
 
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments


Magle Chemoswed Q4 - Delivering on its growth trajectory

Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.